Mohamad Haffar, MD
Gastroenterology · South Charleston, WVNPI 1205995701
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $91,648 of the $117,710 with a category attached, or 77.9%. 40 manufacturers reported payments, led by AbbVie at 32.6% of the total. Reporting peaked in 2020 at $31,493 and has fallen 74.8% since, to $7,934 in 2025. Among gastroenterology clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,197 payments — averaging $98.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$38K
- Gilead$31K
- Pfizer$12K
- Nestle Healthcare Nutrition Inc.$9K
- Intercept Pharmaceuticals, Inc.$8K
- Aimmune Therapeutics, Inc.$5K
- plus $14K from 34 others
What the payments were for
- Consulting fees$3,7503%
- Speaking & faculty fees$91,64878%
- Travel & lodging$1,8392%
- Food & beverage$20,38417%
- Education$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$117,710 in reported general payments places this provider in the 95th percentile of 72 gastroenterology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 33 | $948,727 |
| XifaxanRifaximin | 102 | $331,212 |
| Humira(Cf) PenAdalimumab | 20 | $145,043 |
| LinzessLinaclotide | 160 | $127,492 |
| RezdiffraResmetirom | 22 | $105,222 |
| IbsrelaTenapanor Hcl | 53 | $102,698 |
| CreonLipase/Protease/Amylase | 35 | $80,735 |
| ZenpepLipase/Protease/Amylase | 24 | $77,822 |
| ViberziEluxadoline | 26 | $39,302 |
| TrulancePlecanatide | 24 | $32,889 |
| Alosetron Hcl | 31 | $26,171 |
| GimotiMetoclopramide Hcl | 12 | $25,492 |
| RelistorMethylnaltrexone Bromide | 11 | $24,888 |
| MotegrityPrucalopride Succinate | 22 | $15,401 |
| Mesalamine ErMesalamine | 40 | $13,692 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $2,289 | $948,72733 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Relistor | $4,259 | $388,989137 claims |
| AbbVieLinzess, Creon, Viberzi | $38,338 | $247,529221 claims |
| Madrigal PharmaceuticalsRezdiffra | $22 | $105,22222 claims |
| Ardelyx, Inc.Ibsrela | $586 | $102,69853 claims |
| Aimmune Therapeutics, Inc.Zenpep | $5,372 | $77,82224 claims |
| Evoke Pharma, Inc.Gimoti | $119 | $25,49212 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $857 | $15,40122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 72 gastroenterology providers in West Virginia.
Other gastroenterology in South Charleston
- Cheryl CoxSouth Charleston$1K
- Emily BattleSouth Charleston$739
- Joe WhiteSouth Charleston$438
- Timothy HarperSouth Charleston$188
- Jennifer VeverkaMorgantown$283K
- Shailendra SinghMorgantown$187K
- Shyam ThakkarMorgantown$113K
- Hazem Al-AshhabParkersburg$93K
- Mark VoellingerWheeling$45K
- John NasrMorgantown$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.